FDA approves miniature capsule formulation of omeprazole magnesium for heartburn

The FDA has given final approval to Perrigo Co.’s miniature 20 mg delayed-release omeprazole magnesium capsules for over-the-counter treatment of frequent heartburn., according to a company press release.Approximately 70% smaller than the standard tablet version of omeprazole currently available, the “first-to-market” miniature capsule is intended to “provide a differentiated and preferred product offering for consumers,”…

VIDEO: ‘The future is bright’ for patients treated with RBX2660 for C. difficile

SAN DIEGO — In a Healio video exclusive from Digestive Disease Week 2022, Paul Feuerstadt, MD, FACG, AGAF, discussed studies assessing the investigational biotherapeutic, RBX2660, for the treatment of Clostridioides difficile.“RBX2660 has consistent safety and efficacy regardless of the patient’s medical history as well as their demographics; this again applies to the notion that patients…

Cirrhotic COVID-19 survivors show poor short-term outcomes, no differences long-term

SAN DIEGO — Patients with cirrhosis who survived COVID-19 may not have worsening of underlying disease or death in the long-term compared with cirrhotic patients who never acquired COVID-19, noted data from Digestive Disease Week 2022.“While previous studies have focused on the clinical outcomes of COVID-19 disease in patients with cirrhosis, there has been a…

VIDEO: Tremfya safe, efficacious for moderately to severely active Crohn’s

SAN DIEGO — In this video exclusive, Remo Panaccione, MD, of the University of Calgary, discussed a study assessing the safety and efficacy of Tremfya in patients with moderately to severely active Crohn’s disease.During the GALAXI1, phase 2, double-blind, placebo-controlled, multicenter study, patients were randomly assigned to Tremfya (guselkumab, Janssen) dosed 200 mg, 600 mg…